Month: June 2025

Collaboration enables testing of nitrosamine impurities, allowing sponsors to demonstrate acceptable use of rifampin in drug-drug interaction studies DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced a strategic collaboration with Emery Pharma, a leading analytical and bioanalytical CRO providing testing services under current Good Manufacturing Practice (cGMP) and Good Laboratory Practice (GLP), to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction (DDI) studies, to certify impurities are below the Acceptable Intake (AI) Limit set by U.S. Food and Drug Administration (FDA) guidelines. Fortrea has selected Emery Pharma due to its strong capabilities...

Volta Finance Limited (VTA / VTAS)May 2025 monthly report NOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES Guernsey, June 24, 2025 AXA IM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for May 2025. The full report is attached to this release and will be available on Volta’s website shortly (www.voltafinance.com). Performance and Portfolio Activity Dear Investors, In May, Volta Finance’s net performance reached +3.3% bringing the performance from August 2024 to date to +10.7%. Our investments in CLO Debt and CLO Equity recovered some of their post-liberation day volatility due to improved market sentiment. May saw a more positive macroeconomic environment, helping markets recover most of the losses from the previous month. The 90-day tariff...

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE Vazkepa® supported by strong clinical data package and expected to contribute to Specialty & Primary Care growth in coming years Milan, 24 June 2025 – Recordati today announced a licensing and supply agreement with Amarin to commercialize the marketed cardiovascular medicine, Vazkepa® (icosapent ethyl) across 59 countries, focused in Europe. Vazkepa® is indicated to reduce the risk of cardiovascular events in statin-treated adult patients at high cardiovascular risk with elevated triglycerides and either established cardiovascular disease or diabetes with at least one other cardiovascular risk factor. Vazkepa® was approved in 2021 in the EU and UK and in 2022 in Switzerland based on the REDUCE-IT study, a Phase 3 Cardiovascular...

ALBUQUERQUE, N.M., June 24, 2025 (GLOBE NEWSWIRE) — Array Technologies, Inc. (NASDAQ: ARRY) (the “Company” or “ARRAY”) today announced that, subject to market conditions, it intends to offer $250 million in aggregate principal amount of convertible senior notes due 2031 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities Act of 1933, as amended (the “Securities Act”). ARRAY also intends to grant the initial purchasers of the Notes an option to purchase, for settlement within a 13-day period from, and including the date on which the Notes are first issued, up to an additional $37.5 million aggregate principal amount of Notes. The Notes will be senior, unsecured obligations of ARRAY, and will accrue interest payable semiannually...

OTTAWA, Ontario, June 24, 2025 (GLOBE NEWSWIRE) — Calian Group Ltd. (TSX: CGY), a mission-critical solutions company focused on defence, space, healthcare and strategic growth critical infrastructure sectors, today announced that Chris Pogue will join the company as President, Defence & Space, effective July 7, 2025. In this newly created role, Pogue will lead a high-performance organization that brings together Calian’s Advanced Technologies and Learning business units—leveraging the synergies of its communications and manufacturing solutions alongside its immersive training and simulation expertise to accelerate mission success for defence and space customers alike. “Chris Pogue is one of Canada’s most accomplished leaders in defence and space innovation,” said Kevin Ford, CEO of Calian. “His track record—growing Thales...

Up to $1.25 billion ($250 million upfront) of synthetic royalty funding and up to $750 million in secured debt Innovative partnership enables Revolution Medicines to retain control over pipeline development and global commercialization of daraxonrasib Highlights Royalty Pharma’s unique ability to provide capital at scale to help leading companies achieve their strategic goals Daraxonrasib, in Phase 3 development for pancreatic cancer and non-small cell lung cancer, would be the first targeted therapy to inhibit all major forms of RAS, one of the most common drivers of human cancersNEW YORK, June 24, 2025 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced a $2 billion funding arrangement with Revolution Medicines, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and a senior secured...

Firmware over-the-air updates and remote cryptographic key management provide scalable solutions for addressing IoT security challenges CHANDLER, Ariz., June 24, 2025 (GLOBE NEWSWIRE) — International cybersecurity regulations continue to adapt to meet the evolving threat landscape. One major focus is on outdated firmware in IoT devices, which can present significant security vulnerabilities. To address these challenges, Microchip Technology (Nasdaq: MCHP) is enhancing its TrustMANAGER platform to include secure code signing and Firmware Over-the-Air (FOTA) update delivery as well as remote management of firmware images, cryptographic keys and digital certificates. These advancements support compliance with the European Cyber Resilience Act (CRA) which mandates strong cybersecurity measures for digital products sold in the European...

Castellum, Inc. Announces Creation of New Subsidiary to Focus on Advanced Technology ProductsCastellum, Inc. (the “Company” and “Castellum”) (NYSE-American: CTM) announced the creation of a new wholly owned subsidiary, Castellum Advanced Technology Products, Inc. (“CATP”) – www.castellumus.comVIENNA, Va., June 24, 2025 (GLOBE NEWSWIRE) — Castellum, Inc. (the “Company” and “Castellum”) (NYSE-American: CTM), a cybersecurity, electronic warfare, and software services and solutions company focused on the federal government, today announced the creation of a new wholly owned subsidiary, Castellum Advanced Technology Products, Inc. (“CATP”). CATP will focus on teaming with other leading-edge technology companies, developing technology internally, and potentially taking equity positions in companies that have advanced...

ATLANTA, June 24, 2025 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that Utah-based Walking Comfort, a leading retailer in the local and online footwear market, is using Descartes Sellercloud™ to help drive ecommerce growth by centralizing and synchronizing the management of product listings, inventory, orders and fulfillment across multiple online sales channels. “As the business grew and we expanded to a larger warehouse and more online marketplaces, we realized we needed a more sophisticated inventory and order management system to boost time-savings and operating efficiencies,” said Brad Hendricksen, Accounting and Operations Manager at Walking Comfort. “With Descartes Sellercloud, we have a powerful platform that...

Hong Kong, June 24, 2025 (GLOBE NEWSWIRE) — Garden Stage Limited (NASDAQ: GSIW) (“GSIW” or the “Company”), today announced that on June 23, 2025, the Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). As previously disclosed , the company received a delinquency notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on December 24, 2024 indicating that the Company is not currently in compliance with the minimum bid price requirement set forth in Nasdaq’s Listing Rules for continued listing on the Nasdaq Capital Market, as the closing bid price for the Company’s ordinary shares...